Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Stephen H Gillespie, Angela M Crook, Timothy D McHugh...
https://pubmed.ncbi.nlm.nih.gov/25196020/Actively Recruiting
Led by Johns Hopkins University · Updated on 2026-07-24
860
Participants Needed
9
Research Sites
N/A
Total Duration
Researchers are studying treatment options for children under 10 years old who have drug-susceptible tuberculosis TB. The goal is to see if a shorter 2-month treatment regimen using isoniazid, rifapentine, pyrazinamide, and moxifloxacin is as safe and effective as the standard 4- to 6-month treatment regimen that uses isoniazid, rifampicin, pyrazinamide, and ethambutol. This study also looks at the safety of the shorter regimen in children with and without HIV. Participants will be randomly assigned to one of two treatment groups. One group will receive the standard regimen of 8 weeks of isoniazid, rifampin, pyrazinamide, and ethambutol followed by 16 or 24 weeks of isoniazid and rifampin, depending on disease severity. The other group will receive 8 weeks of daily isoniazid, rifapentine, pyrazinamide, and moxifloxacin. All drugs are given once daily based on the participants weight. During the study, children will be monitored for TB disease-free survival up to 48 weeks after starting treatment and for adverse events over 28 weeks. Researchers will also assess treatment adherence, tolerability, drug levels, and the acceptability of the treatments reported by parents or guardians. Follow-up visits and evaluations will track health outcomes and safety throughout the study period, which lasts up to about 72 weeks from entry.
CONDITIONS
Shortened Regimen for Drug-susceptible TB in Children
K
Kisten Nolan, MPH, BSN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johns Hopkins University
Lead Sponsor
United States Agency for International Development (USAID)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 to 24 weeks depending on regimen and disease severity
Participants receive either the shorter 2-month daily regimen of isoniazid, rifapentine, pyrazinamide, and moxifloxacin or the standard 4- to 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol.
Duration - Up to 72 weeks
Participants are monitored for TB disease-free survival and side effects for up to 72 weeks after starting treatment.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Stephen H Gillespie, Angela M Crook, Timothy D McHugh...
https://pubmed.ncbi.nlm.nih.gov/25196020/Rulan Griesel, Ying Zhao, Bryony Simmons...
https://pubmed.ncbi.nlm.nih.gov/37230101/Tianyu Zhang, Si-Yang Li, Kathy N Williams...
https://pubmed.ncbi.nlm.nih.gov/21659613/Marc Weiner, Radojka M Savic, William R Mac Kenzie...
https://pubmed.ncbi.nlm.nih.gov/26625366/Alexander Berg, James Clary, Debra Hanna...
https://pubmed.ncbi.nlm.nih.gov/35099274/K E Dooley, E E Bliven-Sizemore, M Weiner...
https://pubmed.ncbi.nlm.nih.gov/22472995/Anna Turkova, Hylke Waalewijn, Man K Chan...
https://pubmed.ncbi.nlm.nih.gov/35868341/R Rustomjee, C Lienhardt, T Kanyok...
https://pubmed.ncbi.nlm.nih.gov/18230244/C Pierfitte, R J Royer
https://pubmed.ncbi.nlm.nih.gov/8953821/G A Ellard
https://pubmed.ncbi.nlm.nih.gov/6385429/Johns Hopkins University
Lead Sponsor
United States Agency for International Development (USAID)
Collaborating Sponsor